Targets › HIV
1 program from 1 company in 3 trials: 3 Phase 1; Infectious disease.
Open in Phaseline: the race on HIV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| U.S. Army Medical Research and Development Command | Ad26.Mos4.HIV Recombinant adenovirus 26-vectored HIV-1 vaccine expressing mosaic envelope antigens | HIV | Phase 1 | Human Immunodeficiency Virus | – |
Human Immunodeficiency Virus (3)
protein or peptide (1)
U.S. Army Medical Research and Development Command (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.